|
Originally published In Press as doi:10.1074/jbc.M701826200 on June 14, 2007
J. Biol. Chem., Vol. 282, Issue 32, 23517-23524, August 10, 2007
Paratope and Epitope Mapping of the Antithrombotic Antibody 6B4 in Complex with Platelet Glycoprotein Ib *
Alexandre Fontayne 1,
Bauke De Maeyer 2,
Marc De Maeyer ¶,
Mayo Yamashita||,
Tadashi Matsushita**, and
Hans Deckmyn ¶3
From the
Laboratory for Thrombosis Research, IRC, the Laboratory of Biomolecular Modeling, Department of Chemistry, and ¶BioMacS, KU Leuven Campus Kortrijk, E. Sabbelaan 53, B-8500 Kortrijk, Belgium, the ||Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya 466-8560, Japan, and the **Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan
The monoclonal antibody 6B4 has a potent antithrombotic effect in nonhuman primates by binding to the flexible loop, also known as the -switch region (amino acids 230-242), of glycoprotein Ib (GPIb ). This interaction blocks, in high shear stress conditions, the specific interaction between GPIb and von Willebrand factor suppressing platelet deposition to the damaged vessel wall, a key event in the pathogenesis of arterial thrombosis. To understand the interactions between this antibody and its antigen at the amino acid level, we here report the identification of the paratope and epitope in 6B4 and GPIb , respectively, by using computer modeling and site-directed mutagenesis. The docking programs ZDOCK (rigid body docking) and HADDOCK (flexible docking) were used to model the interaction of 6B4 with GPIb and to delineate the respective paratope and epitope. 6B4 and GPIb mutants were constructed and assayed for their capacity to bind GPIb and 6B4, respectively. From these data, it is found that the paratope of 6B4 is mainly formed by five residues: Tyr27D, Lys27E, Asp28, and Glu93 located in light chain CDR1 and -3, respectively, and Tyr100C of the heavy chain CDR3. These residues form a valley, where the GPIb flexible loop can bind via residues Asp235 and Lys237. The experimental results were finally used to build a more accurate docking model. Taken together, this information provides guidelines for the design of new derivatized lead compounds with antithrombotic properties.
Received for publication, March 2, 2007
, and in revised form, May 30, 2007.
* This work was supported by Instituut voor de Aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen Grant IWT 020473 and by the Sankyo Foundation of Life Science. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org) contains supplemental Table S1.
1 An EU-Research Training Network (HPRN-CT-2002-00253) postdoctoral fellow.
2 A bursary of the IWT.
3 To whom correspondence should be addressed. Tel.: 32-56-246422; Fax: 32-56-246997; E-mail: Hans.Deckmyn{at}kuleuven-kortrijk.be.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Barderas, J. Desmet, P. Timmerman, R. Meloen, and J. I. Casal
Affinity maturation of antibodies assisted by in silico modeling
PNAS,
July 1, 2008;
105(26):
9029 - 9034.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|